At the Americas Committee for Treatment and Research in Multiple Sclerosis held in Dallas, Texas, John DeLuca, PhD, gave a presentation on the assessment of cognitive processing speed in the SUNBEAM trial based on performance on the Symbol Digit Modalities Test (SDMT). Researchers found that compared with interferon beta-1a, ozanimod resulted in sustained improvement in cognitive processing speed through 12 months, further supporting the efficacy of this therapy in relapsing multiple sclerosis. In the total SUNBEAM trial population, 25% of study participants who showed stability at month 6 also showed improvement at month 12. Among those who demonstrated improvement in SDMT score at month 6, greater proportions treated with ozanimod HCI 0.5 mg and 1 mg than with interferon beta-1a sustained improvement at month 12 (63% and 66% vs. 56%, respectively).
Read more:
0 Comments